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Aims: Co-morbid insomnia and obstructive sleep apnea (OSA) represents a highly prevalent 
and debilitating condition, however physicians and researchers are still uncertain as to the 
most effective treatment approach. Several research groups have suggested that these patients 
should initially receive treatment for their insomnia before the sleep apnea is targeted. The 
current study aims to determine whether cognitive and behavioral therapy for insomnia 
(CBT-i) can effectively treat insomnia in patients with co-morbid OSA, and whether its 
effectiveness is impaired by the presence of OSA. 
Methods: A retrospective chart review was conducted to examine 455 insomnia patients 
entering a CBT-i treatment program in a hospital outpatient setting. 314 patients were 
diagnosed with insomnia-alone, and 141 with insomnia a d co-morbid obstructive sleep 
apnea. Improvements in average sleep diary parameters, global insomnia severity, and several 
daytime functioning questionnaires from baseline, to post-treatment, to 3-month follow-up 
were compared between insomnia patients with- and without co-morbid sleep apnea. 
Results: Insomnia patients with co-morbid OSA experienced significant improvements in 
insomnia symptoms, global insomnia severity, and other daytime functioning measures 
during and following treatment. Furthermore, improvements were no different between 
patients with or without co-morbid OSA. Sleep apnea presence and severity were not related 
to rates of insomnia-remission or treatment-resistance following treatment.  
Conclusions: CBT-i is an effective treatment in the presence of co-morbid OSA. This 
information offers support for the suggestion that p tients with co-morbid insomnia and 
obstructive sleep apnea should be treated with CBT-i prior to treatment of the OSA. 
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AHI – Apnea/Hypopnea Index 
CBT-i – Cognitive Behavioral Therapy for Insomnia 
COMISA – Co-Morbid Insomnia and Sleep Apnea 
CPAP – Continuous Positive Airway Pressure Therapy 
ESS – Epworth Sleepiness Scale 
ISI – Insomnia Severity Index 
OSA – Obstructive Sleep Apnea 
RDI – Respiratory Disturbance Index 














Insomnia and Obstructive Sleep Apnea (OSA) are the two most common sleep 
disorders, and frequently co-occur (1, 2). In fact,  recent review found that 27 to 85% of 
OSA patients in sleep disorder clinics report symptoms of co-morbid insomnia, and 17 to 
69% of insomnia patients in sleep disorder clinics fulfil minimal diagnostic criteria for co-
morbid OSA (3). These patients with Co-morbid Insomnia and Sleep Apnea (COMISA) not 
only experience difficulties initiating sleep, maintaining sleep, or waking too early and 
having difficulty returning to sleep, but when sleep is attained, it is marked by repetitive 
respiratory events, post-apneic arousals and fragmented sleep architecture (4). Furthermore, 
as both insomnia and OSA are independently associated wi h significant daytime functioning 
impairments and reduced quality of life, COMISA patien s experience greater detriment in 
these domains, compared to groups of patients with either insomnia, or OSA alone (3, 5). 
Due to the increasing recognition of the prevalence and debilitating nature of COMISA, a 
growing amount of research has recently focused on treatment attempts in this population (3, 
6-8). 
Continuous Positive Airway Pressure (CPAP) therapy is the recommended treatment 
for moderate and severe OSA (9, 10). However, co-morbid insomnia symptoms are 
associated with reduced acceptance and use of CPAP therapy (11-15). The most common 
treatment recommendation for COMISA includes treatment of the insomnia with Cognitive 
and Behavioral Therapy for Insomnia (CBT-i), before initiating treatment of the OSA with 
CPAP therapy (3, 7, 16-18). It is thought that initially targeting the insomnia, and allowing 
patients to initiate and return to sleep quicker throughout the night, will also increase 
subsequent acceptance and use of CPAP therapy. Although this is a logical treatment 
suggestion, only a small handful of research has exmined the suitability and effectiveness of 













CBT-i is the most effective treatment for insomnia, whether it presents as an isolated 
condition, or occurs in the presence of additional co-morbid disorders (19-22). CBT-i is a 
multi-component, non-pharmacological therapy which targets the underlying cognitive, 
behavioral and physiological process and factors which are thought to perpetuate the overall 
insomnia condition (23, 24). Trained sleep therapists or psychologists utilize several 
behavioral (e.g. stimulus control therapy, bedtime restriction therapy), cognitive (e.g. altering 
maladaptive sleep-related cognitions) and psycho-educational (e.g. basic sleep information, 
and sleep hygiene information) tools during weekly therapy sessions, to reduce anxiety and 
arousal associated with sleep, or the sleep environment (24-26). Because CBT-i targets the 
underlying processes believed to perpetuate the insom ia condition, rather than only the 
surface symptoms, improvements are sustained beyond the cessation of therapy (25). 
Only a handful of case studies (27, 28), pilot studies (29-33), and one randomized 
controlled trial (8) have investigated the effectiveness of CBT-i in the COMISA population. 
Earlier case studies and pilot studies resulted in some disagreement over the impact of CBT-i 
in COMISA (3). However, in a recent randomized contr lled trial, Fung and colleagues (8) 
found that patients with COMISA and patients with insomnia-alone experienced similar 
improvements in sleep parameters during CBT-i. The eff ct of CBT-i, versus a sleep 
education control condition, was examined in 39 older adult Veterans with insomnia-alone, 
and 95 older adult Veterans with insomnia and mild OSA. Participants completed a range of 
assessments at baseline, post-treatment, 6-month, and 12-month follow-up. CBT-i sessions 
were delivered by health educators under the supervision of a sleep psychologist, and 
included bedtime restriction therapy, stimulus contr l therapy, and cognitive therapy. At 6-
months, COMISA participants treated with CBT-i displayed significantly greater 
improvements in sleep onset latency and overall sleep quality scores, compared to COMISA 













improvements resulting from CBT-i were similar for participants with insomnia-alone, and 
those with co-morbid mild OSA. Although these findigs provide strong empirical evidence 
supporting the effectiveness of CBT-i in COMISA, more research is required in samples of 
different ages and different levels of OSA severity, to determine whether CBT-i is effective 
in insomnia patients with and without co-morbid OSA. 
It is also possible that some COMISA patients experience insomnia which is 
secondary to their OSA (7, 27, 34). For example, during sleep periods marked by repetitive 
respiratory events and post-apneic arousals, some OSA patients may perceive periods of 
extended wakefulness or broken sleep, and present to sleep clinics with a complaint of 
insomnia (7, 35). If the insomnia complaint is a result of OSA manifestations, it is unlikely to 
improve with CBT-i (36). Some have suggested that such patients should be treated with 
CPAP therapy, which is more likely to improve both the insomnia and OSA (6, 7). One aim 
of the current study is to examine patterns of insomnia improvement and treatment-resistance 
following CBT-i, in COMISA patients and patients with insomnia-alone. It is expected that a 
greater number of COMISA patients will experience trea ment-resistant insomnia due to 
possible casual relationships between the underlying OSA and secondary insomnia 
manifestations in a subset of COMISA patients. 
COMISA is a highly prevalent and debilitating condition which is more difficult to 
treat compared to either disorder presenting alone. Th  most common treatment suggestion 
for COMISA includes initial treatment with CBT-i, to improve the insomnia condition, and 
increase subsequent acceptance and use of CPAP therapy. However, before implementing 
this treatment suggestion, it is essential to establi h the effectiveness of CBT-i in the 
COMISA population. The current study aims to compare the effectiveness of CBT-i in 
patients with insomnia-alone, and patients with COMISA, in treating the daytime and night 














2.1.  Design 
This study used a quasi-experimental design to examine the effectiveness of CBT-i in 
insomnia patients with- and without co-morbid OSA. These patients attended an out-patient 
insomnia treatment program at the Adelaide Institute for Sleep Health, The Repatriation 
General Hospital, Adelaide, South Australia, between F bruary 2004, and November 2015. 
This research was approved by the Social and Behavioral Research Ethics Committee at 
Flinders University of South Australia. All participants gave consent for information to be 
used for research purposes. 
2.2.  Participants 
Participants included 455 consecutive adult patients (Age M = 51.68, SD = 15.65; 
33.1% Male) referred specifically to an insomnia trea ment program at a multi-disciplinary 
sleep clinic, by a General Practitioner or another health professional. Inclusion criteria were: 
consent to have information used for research, aged18 or over, an insomnia diagnosis 
according to DSM-IV criteria (and DSM-V from 2013-2015) performed by a registered 
psychologist (37), completion of baseline overnight polysomnographic sleep study, not 
currently admitted as hospital in-patient, and absence of CPAP therapy for duration of the 
follow-up period. Participants were initially divide  into four groups based on OSA presence 
and severity; no OSA (n = 314, 69%), mild OSA (n = 103, 22.6%), moderate OSA (n = 25, 
5.5%) and severe OSA (n = 13, 2.9%). However, because of the small number of patients in 
the ‘moderate’ and ‘severe OSA’ groups, the mild, moderate, and severe OSA groups were 
collapsed into one COMISA group (n = 141, 31%). Baseline demographic and descriptive 
data between these two groups appears in Table 1. 
The insomnia treatment program cost patients $575 AUD, however upon referral with 













reduced this cost to $50 AUD. Alternatively, Department of Veteran Affairs card holders 
were treated at no charge. These costs were thought to increase the generalizability of these 
findings to patients attending insomnia-treatment programs in ‘real world’ clinical settings. 
2.3.  Screening 
2.3.1. Sleep Studies. Overnight Polysomnographic (PSG) sleep studies were 
routinely completed at baseline as part of the insomnia treatment program, to screen for 
additional sleep disorders and collect information about patients’ objective sleep (Somté 
portable full PSG recorders, Compumedics, Melbourne, Australia). Electrodes were 
configured to record two electroencephalogram channels (C3-A2, C4-A1), two 
electrooculogram channels, one electromyogram channel, two respiratory effort channels, and 
two electromyogram channels to record leg movements. A finger oximeter was attached to 
continuously record oxyhemoglobin saturation. Nasal pressure and oro-nasal airflow were 
recorded with a nasal cannula, and an oro-nasal thermistor. All sleep studies were scored by 
experienced technicians according to AASM criteria (38-40). 
These data were collected from February, 2004 to November, 2015. During this time, 
the study site’s metric for defining OSA presence and severity changed from the Respiratory 
Disturbance Index (RDI), to the Apnea/Hypopnea Index (AHI). Participants entering the 
program prior to 2011 received an RDI (n=333) which included respiratory effort related 
arousals (40), whilst participants entering the program from 2011 onward received an AHI 
score (n=122), encompassing only apneas and hypopneas (41).  As these indices represent 
different manifestations of OSA, different cut-offs were applied to indicate OSA severity; 
none, mild, moderate and severe OSA. For RDI, mild, moderate and severe cut-offs were 
indicated by scores of 15-29, 30-44, and > 45, respectively. Alternatively, for AHI, mild, 














2.4.  Outcome Measures collected at baseline, post-treatment, and three-month 
follow-up. 
2.4.1. One-Week Sleep/Wake Diaries. Sleep diaries are the recommended outcome 
measure for insomnia-treatment research (42). Sleep diaries were used to assess participants’ 
average weekly subjective sleep parameters at baseline and during each follow-up period. 
Participants indicated their nightly; sleep onset latency, wake after sleep onset, and total sleep 
time for one week. Average sleep efficiency was also calculated by dividing average weekly 
total sleep time by time in bed, and multiplying by 100. 
2.4.2.  The Insomnia Severity Index (ISI). The ISI was used to measure 
improvements in insomnia severity during treatment. The ISI is a 7-item questionnaire which 
has been widely used as an outcome measure of insomnia severity in treatment studies (43). 
Scores range from 0 – 28, with higher scores represnting more severe insomnia. The ISI is a 
valid measure of insomnia severity in populations of primary insomnia patients, and has been 
used in the COMISA population (6, 14, 44). ISI scores were also used to categorize insomnia 
remission (ISI<8), and patterns of treatment resistant insomnia (ISI improvement <4) at post-
treatment and 3-month follow-up. 
2.4.3. Daytime Functioning and Impairment Scales. The Epworth Sleepiness 
Scale (ESS) (45) is an 8-item self-report scale which was used to measure changes in 
subjective daytime sleepiness during treatment. Scores range from 0-24 with greater scores 
indicating more daytime sleepiness. The ESS has been reported to have adequate test-retest 
reliability (.82) and internal consistency as measured by Cronbach’s alpha (.88) (45). 
The Flinders Fatigue Scale (46) is a 7-item self-repo t questionnaire which was used 
to measure changes in feelings of fatigue during treatment. Patients answered answer six 
questions such as “was fatigue a problem for you?” on a five-point scale ranging from 0 (not 













possible times during the day, with one point given for each time that is indicated. Possible 
scores on the scale range from 0 to 31, with higher sco es indicating more daytime fatigue. 
The scale has adequate reliability and validity (46-48). 
The Daytime Feelings and Functioning Scale is a 12-item self-report measure which 
was used to assess changes in daytime feelings and functioning during treatment (47). 
Responses to 12 items such as “lacked motivation”, “Had difficulty accomplishing daytime 
tasks”, and “felt lethargic” are added to form an overall score ranging from 0 to 36, with 
higher scores indicating greater daytime impairment. This measure has adequate internal 
consistency, discriminant validity and is sensitive to treatment-related changes in reported 
daytime functioning (47).  
2.4.4. The Dysfunctional Attitudes and Beliefs about Sleep scale. The 
Dysfunctional Attitudes and Beliefs about Sleep-12 scale is a 12-item self-report 
questionnaire which assesses participants’ agreement with dysfunctional or maladaptive 
beliefs, appraisals, attributions and attitudes about sleep (49). Participants indicate their 
agreement with each item on a scale of 0 – 100, with possible responses ranging from 
“strongly disagree” to “strongly agree”. A total score is calculated by finding the average 
score of all 12 items. Total scores range from 0 – 1 0, with higher scores representing greater 
agreement with dysfunctional attitudes and beliefs about sleep. Morin and colleagues (49) 
report adequate internal consistency as measured by Cronbach’s alpha (.77). 
2.4.5. The Depression, Anxiety and Stress Scale. The Depression, Anxiety and 
Stress Scale (50) is a 42-item self-report questionnaire which was used to measure symptoms 
of depression, anxiety and stress before and after CBT-i. The three sub-scale scores range 
from 0 – 42, with higher scores indicated more depression, anxiety or stress. The subscales of 













alpha (.87 - .94), as well as the overall scale (.93) and good convergent and discriminant 
validity when compared to other measures of depression, anxiety, and stress (51, 52). 
2.5.  Procedure for Insomnia Treatment Program 
 Following a diagnosis of insomnia, performed by a registered psychologist 
(Psychologists had 5 – 35 years of experience diagnosing and treating insomnia disorders), 
patients completed the baseline assessment (sleep diary and questionnaires), before an 
overnight home-based PSG sleep study was undertaken o screen for the presence of any 
additional sleep disorders. Patients then attended a group sleep education session (group sizes 
of 6-10 patients) which lasted two hours. These education sessions included information 
about the definitions and nature of insomnia, basic sleep information such as 90 min sleep 
cycles of deep and light sleep (53), positive sleep hygiene, the interplay between cognitions, 
behavior and sleep, and the effect of sleep medications. Patients then attended 4-6 
personalized treatment consultations with an experienced sleep psychologist. During these 
sessions, psychologists used a range of cognitive, behavioral, and educational components to 
target specific mechanisms underlying each patients’ insomnia condition (54). Follow-up 
assessments (sleep diaries and questionnaires) were completed again at post-treatment, and 





















Table 1. Demographic and Baseline Descriptive Data. 
















-5.67 < .001* 






-4.51 < .001* 






-6.36 < .001* 




























































Dysfunctional Beliefs and 





























COMISA – Co-morbid Insomnia and Sleep Apnea 
 
2.6.  Overview of Data Analysis 
All data were analyzed with IBM SPSS (Version 22). Linear Mixed Models analyses 
were undertaken to examine differences in insomnia improvements during treatment between 
patients with insomnia-alone, and COMISA. As age and gender differed between groups at 













square analyses were used to examine rates of insomnia remission and treatment-resistance 
during therapy.  
2.7. Missing Data 
Of the 455 participants beginning treatment, missing leep diary data were observed 
at baseline, post-treatment, and 3-months in 24%, 33 , and 49%, respectively. Missing ISI 
data were observed in 35%, 60%, and 61%, at each subseq ent follow-up, respectively. 
Finally, missing data on other outcome questionnaires were observed in 13%, 44%, and 47% 
at each subsequent follow-up, respectively. Pearson Chi-Square tests revealed that rates of 
missing ISI data at baseline differed significantly between patients with COMISA (45% 
missing) and those with insomnia-alone (31% missing; χ2(1) = 8.12, p = .004). There were no 
other significant differences in rates of missing data between groups, for any other outcomes 
at any follow-up. Patterns of missing data were considered to be missing at random, 
according to pre-defined criteria (55). Missing data occurred primarily because of lack of 
systematic collection of each outcome from each patient, and the modification and delayed 
introduction of some questionnaires (e.g., the ISI)to the questionnaire battery over the 12-
year period. Therefore, patterns of missing data were thought to be unrelated to patients’ 
study group or disease severity. Linear Mixed Models analyses were chosen over the 
ANOVA approach due to the ability to handle randomly issing data (55, 56). 
3. RESULTS 
3.1.  Effect of CBT-i 
It was predicted that patients with co-morbid insomnia and sleep apnea (COMISA) 
would experience significant improvements in insomnia symptoms during CBT-i. COMISA 
patients showed statistically significant improvement in all sleep diary (Table 2) and 
questionnaire measures (Table 3) from baseline to 3-month follow-up. Similarly, as expected, 













as the majority of questionnaire measures during treatment. The only exception to this was 
the Epworth Sleepiness Scale which showed no significa t difference from baseline to post-
treatment (p = .12), and a small significant decrease between post-treatment and 3-month 
follow-up (p = .002), however no overall significant effect of time. 
3.2.  Group Comparisons 
It was expected that patients with COMISA might show smaller improvement of 
outcome measures than the patients with insomnia-alone. However, there were no statistically 
significant interactions in improvements in the majority of sleep diary parameters or 
questionnaire outcomes (See Tables 2 and 3, and Figures 1 and 2). The only significant sleep 
diary interaction showed that COMISA patients experienced slightly greater improvements in 
total sleep time than patients with insomnia-alone during treatment (As seen in Table 2, 
Figure 1). As age and gender differed between groups at baseline, significant interactions 
were repeated while controlling for these variables. After controlling for age and gender, the 
interaction between group and time on total sleep time was no longer statistically significant 
(F(569.17) = 0.49, p = 0.61). 
 COMISA patients showed slightly less improvement in the ISI, and the DBAS scale 
during treatment, compared to patients with insomnia-alone (Table 3, Figure 2). After 
controlling for gender and age, interaction terms were no longer statistically significant for 
ISI (F(463.53) = 2.63, p = .07), or DBAS outcomes (F 568.89) = 1.28, p = .28). Finally, 
COMISA patients experienced significantly greater reductions in the Epworth Sleepiness 
Scale (ESS) compared to patients with insomnia-alone (Table 3, Figure 2). This interaction 
remained significant after controlling for age and gender. There were no statistically 
significant interactions in improvements in the remaining questionnaire measures during 













To further investigate the association of OSA severity and insomnia improvements 
during CBT-i, change scores were computed for each sleep diary sleep parameter from 
baseline to post-treatment, and baseline to three-month follow-up (e.g. change in total sleep 
time from baseline to post-treatment, change in total sleep time from baseline to three-month 
follow-up, etc.). Correlational analyses revealed that OSA severity (AHI/RDI) was not 
related to changes in any sleep parameter during treatment (all r < .1, all p > .05). 
 
 
Table 2. Changes in sleep diary measures during treatment for patients with insomnia-alone, 
and COMISA. 
 COMISA = Co-morbid insomnia and sleep apnea 
* p < .001 main effect of time per group 







M (95%CI ) 
COMISA  
M (95%CI ) 
Interaction 
F df p 
Total Sleep Time (min) 
Baseline 331.7 (10.3) 306.8 (15.0) 4.33 570.70 .014  ̂
Post-Treatment 366.3 (10.5) 330.8 (15.8)    
3-Months 373.3 (11.0) 365.1 (17.0)    
Change by 3-
Months 
41.7 (12.4)* 58.4 (19.0)*    
Sleep Onset Latency (min) 
Baseline 62.59 (5.02) 64.41 (7.27) 0.12 512.26 .889 
Post-Treatment 27.42 (5.12) 29.78 (7.87)    
3-Months 24.66 (5.47) 24.37 (8.56)    
Change by 3-
Months 
-37.94 (7.44)* -40.03 (11.33)*    
Wake After Sleep Onset (min) 
Baseline 102.56 (6.93) 113.73 (10.18) 0.49 543.56 .614 
Post-Treatment 42.03 (7.17) 52.36 (10.84)    
3-Months 43.58 (7.67) 47.39 (12.18)    
Change by 3-
Months 
-58.98 (10.40)* -66.35 (16.05)*    
Sleep Efficiency (%) 
Baseline 67.28 (1.72) 64.53 (2.53) 1.87 551.47 .156 
Post-Treatment 83.84 (1.77) 79.39 (2.69)    
3-Months 84.41 (1.88) 83.48 (2.97)    
Change by 3-
Months 



















F Df p 
Insomnia Severity Index    
Baseline 19.9 (0.6) 18.0 (1.1) 4.56 449.67 .011^ 
Post-Treatment 9.5 (0.8) 9.6 (1.3)    
3-Months 7.6 (0.8) 8.2 (1.3)    
Change by 3-Months -12.2 (1.10)** -9.8 (1.80)**    
Epworth Sleepiness Scale    
Baseline 5.3 (0.5) 6.5 (0.7) 3.42 507.97 .034 
Post-Treatment 5.9 (0.6) 5.8 (0.8)    
3-Months 4.9 (0.6) 5.2 (0.9)    
Change by 3-Months -0.4 (0.67) -1.3 (0.97)*    
Flinders Fatigue Scale    
Baseline 18.9 (0.7) 17.5 (1.1) 1.59 565.30 .205 
Post-Treatment 12.3 (0.9) 11.2 (1.3)    
3-Months 10.0 (0.9) 10.2 (1.3)    
Change by 3-Months -8.8 (1.19)** -7.3 (1.78)**    
Daytime Functioning    
Baseline 17.9 (0.8) 17.2 (1.2) 1.49 509.59 .227 
Post-Treatment 10.9 (0.9) 11.4 (1.4)    
3-Months 9.4 (1.0) 9.9 (1.5)    
Change by 3-Months -8.5 (1.13)** -7.3 (1.71)**    
Dysfunctional Beliefs and Attitudes about Sleep    
Baseline 40.2 (1.0) 37.7 (1.5) 5.38 561.00 .005^ 
Post-Treatment 28.2 (1.2) 27.7 (1.9)    
3-Months 25.1 (1.3) 26.5 (1.9)    
Change by 3-Months -15.1 (1.56)** -11.2 (2.36)**    
Depressive Symptoms    
Baseline 12.07 (1.14) 12.67 (1.64) 0.26 477.16 .975 
Post-Treatment 7.98 (1.26) 8.82 (1.91)    
3-Months 6.81 (1.31) 7.56 (1.91)    
Change by 3-Months -5.26 (1.51)** -5.11 (2.17)**    
Anxiety Symptoms    
Baseline 7.78 (0.84) 7.02 (1.20) 0.87 462.77 .419 
Post-Treatment 5.01 (0.95) 5.02 (1.40)    
3-Months 4.86 (0.99) 3.93 (1.39)    
Change by 3-Months -3.12 (1.12)** -3.09 (1.56)**    
Stress    
Baseline 17.10 (1.06) 14.77 (1.51) 2.34 500.73 .098 
Post-Treatment 10.94 (1.17) 10.13 (1.77)    
3-Months 9.26 (1.21) 9.19 (1.80)    
Change by 3-Months -7.84 (1.48)** -5.59 (2.15)**    
COMISA = Co-morbid insomnia and sleep apnea,  
*p < .01 main effect of time per group 
** p < .001 main effect of time per group 

























































































































































3.3. Responder Analyses 
 The responder analysis compared the rates of insomia remission (ISI<8) between the 
two groups. At post-treatment, rates of insomnia remission were not statistically different 
(χ2(1) = 1.35, p = .25) for patients with COMISA (36.0%) and insomnia-alone (45.5%). At 3-
month follow-up, rates of insomnia remission were also not statistically different, (χ2(1) = 
1.16, p = .28), for patients with COMISA (52.9%) and insomnia-alone (61.7%). 
 Finally, to investigate the proportion of patients who experienced a pattern of 
‘treatment-resistant insomnia’ during treatment, participants with less than 4-points 
improvement in the ISI from baseline to post-treatment and baseline to three-month follow-
up were compared between groups. From baseline to post-treatment, rates of insomnia non-
response were not significantly different (χ2(1) = 0.05, p = .83) between patients with 
COMISA (18.6%) and insomnia-alone (20.2%). From baseline to three-month follow-up, 
rates of treatment-resistant insomnia were also not significantly different (χ2(1) = 0.89, p = 
.35) between patients with COMISA (17.1%) and insomnia-alone (11.4%). Furthermore, 
among only patients with COMISA, levels of OSA severity (mild, moderate and severe) were 
not significantly related to treatment-resistant insomnia (χ2(2) = 0.68, p = .71), indicating that 
OSA severity did not influence rates of non-improvement. 
4. DISCUSSION 
            The current results suggest that CBT-i is an effective insomnia treatment in the 
presence of OSA. Specifically, COMISA patients experienced significant robust 
improvement in all sleep and daytime functioning variables during CBT-i. Furthermore, the 
effectiveness of CBT-i was not decreased by the presence or severity of co-morbid OSA, 
when compared to patients with insomnia-alone. These findings offer support for an 
important aspect of the current popular treatment suggestion; that COMISA patients can be 













(17, 18). Research investigating the impact of sequential CBT-i and CPAP therapy is 
currently being conducted (17, 57, 58). 
In the current study, COMISA patients experienced significant improvements in 
subjective sleep parameters, symptoms of fatigue, sle piness, daytime functioning, 
dysfunctional sleep-related thinking patterns, and global insomnia severity, from baseline to 
follow-up periods. For example, among COMISA patients, reported total sleep time increased 
by 24.1 minutes, sleep onset latency estimates decreased by 34.6 minutes, wake after sleep 
onset decreased by 61 minutes, and sleep efficiency increased by 14.9% by post-treatment. 
These improvements are also comparable to those observed in a recent meta-analysis of 
CBT-i in patients with insomnia-alone (19), which found that CBT-i resulted in 
improvements compared to non-treatment control groups in total sleep time of 7.6 minutes, 
sleep onset latency of 19 minutes, wake after sleep onset of 26 minutes, and sleep efficiency 
of 10% by post-treatment. Thus, the improvements from CBT-i in the COMISA patients of 
the present study were as great, if not greater than, t ose with insomnia-alone from the recent 
meta-analysis. 
COMISA patients experienced significantly greater improvements in ESS scores 
during treatment. This interaction remained significant after controlling for age and gender. 
This difference was due to COMISA patients beginning treatment with significantly greater 
daytime sleepiness which was reduced to similar levels to patients with insomnia-alone, by 3-
month follow-up. ‘Excessive daytime sleepiness’ is a central symptom of OSA, and it is 
unsurprising that COMISA patients had increased sleep propensity at baseline (59). 
Importantly, COMISA patients did not experience significantly elevated sleepiness at post-
treatment with the use of bedtime restriction therapy. One concern over the use of bedtime 
restriction therapy in COMISA relates to the effect of bedtime restriction therapy on 













data indicate that the use of bedtime restriction therapy in COMISA patients with mild, 
moderate and severe OSA, does not lead to significatly increased levels of sleepiness by 
post-treatment. However, levels of sleepiness should be closely monitored from week-to-
week of CBT-i in COMISA patients, and bedtime parameters modified accordingly to ensure 
patients’ safety. Future studies may wish to replicate this analysis with a range of additional 
outcome measures (e.g., objective driving performance, and reaction time tasks) administered 
before, during, and after CBT-i in patients with and without co-morbid OSA. 
These results suggest that the effectiveness of CBT-i is not impaired by the presence 
of co-morbid OSA. Some researchers have indirectly cast doubt on the effectiveness of CBT-
i for patients with COMISA, by suggesting that a significant number of COMISA patients 
experience insomnia as a secondary symptom of their OSA (6, 7, 35). For example, OSA is 
associated with repetitive post-apneic arousals from sleep, and it is possible that some 
patients perceive periods of wakefulness following these arousals, and present to sleep clinics 
with a complaint of insomnia (27). While their OSA diagnosis remains stable, these 
‘secondary insomnia’ patients would be expected to show very little response to CBT-i, and 
consequently, would create a pattern of reduced improvements observed for the COMISA 
group as a whole. However, in the current study, as COMISA patients and those with 
insomnia-alone experienced comparable improvements in both night time and daytime 
symptoms of insomnia during CBT-i, regardless of OSA severity, it is unlikely that a large 
proportion of COMISA patients were suffering from insomnia which was secondary to their 
OSA. 
To examine patients in each condition who showed little response to CBT-i, 
‘treatment-resistant insomnia’ was defined as less than 4-points improvement in the Insomnia 
Severity Index during treatment. From baseline to three-month follow-up, 17.1% of COMISA 













insomnia-alone. This difference was not statistically significant, suggesting that co-morbid 
OSA does not increase rates of insomnia non-response during CBT-i. Furthermore, no 
significant differences were observed in rates of insomnia remission between groups at either 
follow-up, suggesting that co-morbid OSA does not reduce rates of insomnia-remission 
following CBT-i. As rates of treatment-resistant insomnia were similar between COMISA 
and insomnia-only groups, it is unlikely that a large proportion of the COMISA group were 
suffering from insomnia as a secondary symptom of their OSA. However, it is possible that 
some of the COMISA non-responders will experience further insomnia improvements after 
starting CPAP (7). 
The current results should be interpreted in light of several limitations. Firstly, these 
data were collected from clinical patients seen over a 12-year period at an out-patient 
insomnia treatment clinic. Although great care was taken to collect and record sleep diary and 
questionnaire data at each follow-up period, some loss of data is inevitable due to patient 
non-compliance and withdrawal, changes in the questionnaire battery, and non-systematic 
recording of outcome data. Although missing data were defined as missing at random, 
according to pre-defined criteria (55), it is possible that some patients who experienced less 
insomnia-improvement were also more likely to have missing follow-up data, thereby 
resulting in a small increase in estimates of insomnia-improvements during treatment. 
However, as rates of missing data were similar betwe n the insomnia-only, and COMISA 
groups, this pattern of missing data is very unlikely to effect the primary conclusions of the 
study. Unfortunately, no control condition was used. As these data reflect clinical patients 
who commonly paid for treatment, it was unfeasible to mploy a placebo control condition. 
Previous research has documented the benefits of CBT-i over a placebo control condition in 
COMISA patients (8). Furthermore, CBT-i is already a well-established treatment, and the 













COMISA and insomnia-alone, which should not necessarily require a control condition 
against an established treatment. Finally, these wer patients who specifically sought 
insomnia treatment with a primary complaint of insomnia, rather than more general sleep 
laboratory patients, or community-dwelling individuals suffering from insomnia or COMISA. 
It is possible that COMISA patients who seek insomnia treatment are more likely to 
experience improvement with CBT-i, compared to patients who seek treatment primarily for 
symptoms of OSA who are later found to have co-morbid insomnia, or those who do not seek 
treatment. For example, if COMISA patients with a primary complaint of OSA were offered 
CBT-i, it is possible that they would be more likely to reject treatment or become 
disinterested over time. It will be important for future research to determine whether a ‘chief 
complaint’ of insomnia vs. OSA is associated with the effectiveness of different treatment 
options in the COMISA population (61).  
4.1. Conclusion 
Co-morbid insomnia and sleep apnea is a highly prevalent and debilitating condition, 
which is associated with a unique set of complexitis hat can limit effective treatment 
options. The most common treatment suggestion for COMISA patients is to use CBT-i to 
improve the insomnia symptoms, before initiating CPAP therapy to treat the OSA (3, 18, 62). 
The current results suggest that CBT-i is an effectiv  treatment in the COMISA population, 
and that the effectiveness of CBT-i is not impaired by the presence or severity of co-morbid 
OSA. In fact, COMISA patients may experience slightly greater reduction of daytime 
sleepiness during CBT-i, compared to patients with insomnia-alone. Therefore, CBT-i should 
be considered as an initial treatment option among COMISA patients, which not only 
improves insomnia symptoms, but may improve subsequent acceptance and use of CPAP 
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1. Co-morbid insomnia and obstructive sleep apnea commonly co-occur. 
2. The effectiveness of CBT-i is not reduced in patients with co-morbid sleep apnea. 
3. CBT-i may also improve subsequent CPAP use in patients with co-morbid insomnia 
and sleep apnea.  
